Compare Macy's Inc (M) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Medpace Holdings Inc — how do they compare? Macy's Inc trades at $22.67 (market cap $5.95B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.8× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Medpace Holdings Inc for 14 Days on average.
| M | MEDP | |
|---|---|---|
Market Cap | $5.95B | $16.82B |
Volume | 6,030,644 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $630.19 |
52-Week Low | $16.51 | $393.42 |
Typical Hold Time | 58 Days | 14 Days |
Enterprise Value | $9.75B | $16.44B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.79 with strong valuation metrics including a P/E of 8.35 and P/S of 0.27, suggesting potential undervaluation. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.63 exceeding expectations by 70%. Technical indicators show a bullish trend with support at $22 and resistance at $23-24, while the RSI at 28.95 suggests potential oversold conditions. Recent news highlights Macy's 'Bold New Chapter' strategy driving digital transformation and sales growth.
The outlook remains cautiously optimistic with a 3.5% dividend yield providing income support. Analyst consensus targets $24.25 with 32% buy ratings, though execution risks persist amid retail sector challenges. Key catalysts include continued digital transformation success and margin improvement, while risks involve competitive pressures and uneven quarterly performance.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
